Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology Business
Positive Kuvan Pivotal Phase 3 Trial Results Published in the Lancet
August 27th, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced that final results from the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3 clinical trial were published in the August 11, 2007, issue of The Lancet. The study suggests that treatment with Kuvan results in significant reductions in blood Phe levels in some phenylketonuria (PKU) patients. Kuvan, an investigational oral small molecule for the treatment of PKU, is being developed in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. "This marks the first published Kuvan clinical study, and we expect additional publications in the coming months to build on the collection of data...
Source: Clinical Trials Week (2007-08-27)
|
